Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02601430 · ClinicalTrials.gov registry record · NA

BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI

A NA study of Peripheral Arterial Disease and Critical Limb Ischemia, sponsored by Zimmer Biomet.

Completed
Registry status
NA
Development phase
5
Enrollment target
1
Study location

NCT02601430 is a NA study of Peripheral Arterial Disease and Critical Limb Ischemia that has completed, run by Zimmer Biomet. The registered enrollment target is 5 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02601430, a NA study of Peripheral Arterial Disease and Critical Limb Ischemia, has completed, sponsored by Zimmer Biomet.

COMPLETED
Registry status
NA
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if an MRI technique called Blood Oxygen Level Dependent, or BOLD, can be used to evaluate blood flow in the leg before and after treatment with standard endovascular therapy in patients with chronic lower limb ischemia.

Interventions

  • OTHER BOLD-MRI

Study Locations (1)

Illinois

  • St. John's Hospital - Springfield

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2016-02
Est. Completion 2016-10
Phase NA

Sponsor

Zimmer Biomet

115 total trials

What the Registry Record Tells You About NCT02601430

The ClinicalTrials.gov registry entry for NCT02601430 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower). The listed sponsor is Zimmer Biomet, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which BOLD-MRI is the first listed.

NCT02601430 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT02601430 about?

NCT02601430 is a clinical study titled "BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI". The purpose of this study is to determine if an MRI technique called Blood Oxygen Level Dependent, or BOLD, can be used to evaluate blood flow in the leg before and after treatment with standard endovascular therapy in patients with chronic lower limb ischemia.

What is the current status of trial NCT02601430?

This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2016-02. Estimated completion is 2016-10.

What conditions does trial NCT02601430 study?

This clinical trial studies the following conditions: Peripheral Arterial Disease, Critical Limb Ischemia.

What interventions are being tested in trial NCT02601430?

The interventions under investigation include: BOLD-MRI (OTHER).

Who is sponsoring clinical trial NCT02601430?

This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02601430 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Arterial Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.